Alvino, V. V., Kilcooley, M., Thomas, A. C., Carrabba, M., Fagnano, M., Cathery, W. R., ... Madeddu, P. R. (2020). In vitro and in vivo preclinical testing of pericyte-engineered grafts for the correction of congenital heart defects: Pericytes and heart defects. *Journal of the American Heart Association*, [e014214]. https://doi.org/10.1161/JAHA.119.014214

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
10.1161/JAHA.119.014214

Link to publication record in Explore Bristol Research
PDF-document

This is the final published version of the article (version of record). It first appeared online via American Heart Association and Wiley at https://www.ahajournals.org/doi/full/10.1161/JAHA.119.014214?af=R. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms
In Vitro and In Vivo Preclinical Testing of Pericyte-Engineered Grafts for the Correction of Congenital Heart Defects

Valeria Vincenza Alvino, MSc; Michael Kilcooley, MSc; Anita C. Thomas, PhD; Michele Carabba, PhD; Marco Fagnano, MSc; William Cathery, MSc; Elisa Avolio, PhD; Dominga Iacobazzi, PhD; Mohamed Ghorbel, PhD; Massimo Caputo, MD; Paolo Madeddu, MD

Background—We have previously reported the possibility of using pericytes from leftovers of palliative surgery of congenital heart disease to engineer clinically certified prosthetic grafts.

Methods and Results—Here, we assessed the feasibility of using prosthetic conduits engineered with neonatal swine pericytes to reconstruct the pulmonary artery of 9-week-old piglets. Human and swine cardiac pericytes were similar regarding anatomical localization in the heart and angiogenic profile following isolation and culture expansion. Like human pericytes, the swine surrogates form clones after single-cell sorting, secrete angiogenic factors, and extracellular matrix proteins and support endothelial cell migration and network formation in vitro. Swine pericytes seeded or unseeded (control) CorMatrix conduits were cultured under static conditions for 5 days, then they were shaped into conduits and incubated in a flow bioreactor for 1 or 2 weeks. Immunohistological studies showed the viability and integration of pericytes in the outer layer of the conduit. Mechanical tests documented a reduction in stiffness and an increase in strain at maximum load in seeded conduits in comparison with unseeded conduits. Control and pericyte-engineered conduits were then used to replace the left pulmonary artery of piglets. After 4 months, anatomical and functional integration of the grafts was confirmed using Doppler echography, cardiac magnetic resonance imaging, and histology.

Conclusions—These findings demonstrate the feasibility of using neonatal cardiac pericytes for reconstruction of small-size branch pulmonary arteries in a large animal model. (J Am Heart Assoc. 2020;9:e014214. DOI: 10.1161/JAHA.119.014214.)

Key Words: congenital heart disease • grafts • pericytes • tissue engineering

Congenital heart disease (CHD) is the most common type of birth defect. Worldwide, 1.35 million babies are born with CHD each year, of which ~5000 are in the United Kingdom alone.1,2 One major problem in the correction of congenital cardiac defects is that prosthetic grafts can only remodel through repopulation by invading cells from neighbor tissues and the circulation. This spontaneous reparative process is not rapid enough to prevent a progressive mismatch between the graft and recipient’s heart. In severe cases, like tetralogy of Fallot, a palliative “shunt” operation becomes necessary to allow to direct blood flow to the lungs and relieve cyanosis before the definitive correction. This temporal window may provide a scope for expanding cardiac cells from surgery leftovers to generate living prostheses. Prostheses endowed with immediate growing capacity ahead of implantation could be better suited to match the rapid growth of a baby’s heart than the currently available acellular grafts.

Our previous study has shown that leftovers of palliative surgery can be used to isolate and expand a population of cardiac stromal cells with the characteristics of pericytes.3 These CPs have the advantage of being clinically approved for use in cardiac surgery.3 Compared with competitive solutions, such as vein-derived autologous endothelial cells (ECs) or peripheral blood-derived endothelial progenitor cells,4–6 CPs may have the advantage of being tissue specific and capable of differentiating into vascular smooth muscle cells and producing extracellular matrix (ECM) proteins.3 Moreover, CPs may favor graft endothelialization through their powerful angiocrine secretome.3 In an initial manufacturing attempt, we seeded human neonatal CPs onto CorMatrix, a decellularized porcine ECM clinically approved for use in cardiac surgery.3 After 3-week culture in a flow bioreactor, the conduit was colonized by the proliferating seeded CPs.
Clinical Perspective

What Is New?

- We have successfully isolated pericytes from the heart of piglets and expanded them to engineer clinical-grade extracellular matrix scaffolds.
- We have provided evidence of feasibility of using a pericyte cellularized scaffold for reconstruction of the pulmonary artery in a piglet model.

What Are the Clinical Implications?

- Currently, repeated interventions are required because of the limited remodeling capacity of the acellular material used for correction of cardiac defects.
- In severe cases, palliation becomes necessary before a definitive surgery correction.
- Cardiac pericytes available from leftover tissue of palliative repair could be used to engineer clinical-grade matrix conduits ready for implantation at the occasion of definitive correction of the pulmonary artery defect.

To make a step forward in the translational pathway, we have now designed a new study aimed at testing the feasibility of implanting CP-engineered conduits in piglets using the same procedure utilized to reconstruct branch pulmonary arteries (PAs) in CHD patients. Human CPs represent the final cellular product. However, preclinical testing of human cells in piglets would require early chronic immunosuppression, which could result in confounding and ethically unacceptable adverse effects.7–9 As a surrogate, we used allogeneic CPs isolated from littermates of the recipient piglet after demonstration of similarities with neonatal human CPs.

Methods

The article adheres to the American Heart Association journals’ implementation of the Transparency and Openness Promotion Guidelines. In accordance with this policy, authors will make the data, methods used in the analysis, and materials used to conduct the research available to any researcher for purposes of reproducing the results or replicating the procedure.

Ethics

Institutional review board approval for the study was obtained, according to the guidelines noted in the Journal Instructions to Authors. Animal experiments were performed in accord with institutional guidelines and followed the principles stated in the Guide for Care and Use of Laboratory Animals published by the National Institutes of Health in 1996 and in the Animals (Scientific Procedures) Act published in 1986. The protocol was covered by the UK Home Office ethical approval PPL 30/3019 and PF6E6335D. The report of experimental data follows the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines.10

Collection of Cardiac Tissue for CP Isolation

Cardiac tissue and peripheral blood were collected from 4-week-old large white/Landrace piglets for isolation/expansion and characterization of swine CPs (sCPs) and peripheral blood mononuclear cells, respectively. Sample attribution to experimental analyses is provided in Table S1.

In Situ Immunohistochemistry and Immunocytochemistry Characterization of sCPs

Details of the methodology used for immunofluorescent microscopy studies are reported in Data S1. The list and source of antibodies are reported in Table S2.

Production of sCP Stocks

Isolation and expansion of sCPs were performed using an adaptation of the good manufacturing practice–compliant standard operating procedure previously used on human neonatal hearts (details in Data S1).3 At passage 2, cells were split for further expansion or generation of frozen stocks.

Assessment of sCP Characteristics

Cell were studied at passage 5/6, using from 3 to 7 biological replicates (run in triplicate), unless otherwise specified. Antigenic profile: Immunofluorescence microscopy (N=7) and flow cytometry analyses (N=3) were performed using the procedures and antibodies described in Data S1 and Tables S2 and S3. Viability, growth curves, and doubling time: Three fresh or frozen-thawed sCP lines were seeded onto a 6-well plate at a density of 3000/cm.2 They were detached at days 4, 5, 6, 7, and 8 of culture and counted using trypan blue (Thermo Fisher Scientific, Loughborough, UK). Clonogenic assay: The test was performed on 2 sCP lines at passage 3, using a motorized device connected to the flow cytometric sorter (Cyclone; Beckman Coulter, Brea, CA). A comparative assay between fresh and frozen-thawed sCPs was performed to assess whether both conditions allow for the generation of clones. Expression of angiogenic factors: Quantitative PCR was performed on cells (N=5 biological replicates) cultured under normoxia (21% oxygen) using a Quanta Studio 6 Flex Real-Time PCR system (Applied Biosystems, Foster City, CA). mRNA expression level was
determined using the 2-ΔCt method. Swine pulmonary artery ECs (sPAECs) were used as control. Taqman probes used in these studies are reported in Table S4. **Secretion of angiogenic factors:** Dedicated antihuman ELISA kits (R&D Systems, Minneapolis, MN, US) were used to measure immunoreactive levels of VEGF-A (vascular endothelial growth factor A), ANG1 (angiopoietin 1), ANG2 (angiopoietin 2), and FGF-2 (fibroblast growth factor 2) proteins in sCPs.

**Figure 1.** Characterization of swine cardiac pericytes. (A and B) Perivascular localization of sCPs in situ. Immunofluorescence images showing the localization of CD31+/CD34+/NG2+ CPs in swine hearts around capillaries (A) and arterioles (B). Inserts showing CD34 labeled in green fluorescence, NG2 in red, and CD31 in white; nuclei are recognized by blue fluorescence of DAPI. Arrows indicate CPs around capillaries and an arteriole. Images taken at 200× magnification. (C) Phase contrast microscopy image of sCPs displaying spindle-shape features (magnification, ×100). (D and E) Graphs showing the growth curve (D) and viability (E) of 3 sCP lines that were seeded at 3000 cells/cm² at day 1 and detached and counted at days 4, 5, 6, 7, and 8 of culture. (F) Immunofluorescence microphotographs showing the expression of neural/glial antigen 2 (NG2) and platelet-derived growth factor receptor beta (PDGFRB), vimentin, CD73, cardiac transcriptional factor GATA-binding protein 4 (GATA-4), and the stemness markers, sex determining region Y-box 2 (SOX-2) and octamer-binding transcription factor 4 (OCT-4). Cells are negative for NANOG and the endothelial cell markers, vascular endothelial-cadherin (VE-cadherin) and CD31. sCPs express alpha-smooth muscle actin (α-SMA) and calponin (CALP) and are negative for transgelin (TAGLN), smoothelin (SMTN), and smooth muscle myosin heavy chain (SMMHC). Expression of Ki67 is indicative of proliferating cells. DAPI (blue) identifies nuclei. Scale bars=100 μm. (G) Bar graph represent the mean±SEM of 7 biological replicates from immunocytochemistry studies. Fluorescence was normalized by nuclei count. (H and I) Flow cytometry analysis of 3 sCP lines at P5. (J and K) Immunofluorescent images and flow cytometry histograms are also shown for swine pulmonary artery endothelial cells (PAECs) (J) and peripheral blood mononuclear cells (PBMCNs; K). APC indicates allophycocyanin; BF, bright field; CD, cluster of differentiation; DAPI, 4’,6-diamidino-2-phenylindole; FITC-A, fluorescein-area; PE-A, phycoerythrin-area; PE-Cy7, phycoerythrin–cyanine 7; sCP, swine cardiac pericytes.
conditioned media (CM) from sCPs, which were cultured under normoxia (N=4 biological replicates). Endothelial network formation: The capacity of cells to form networks on Matrigel was assessed using sCPs or sPAECs alone or both in coculture (N=4 biological replicates). In addition, network formation capacity of sPAECs was assessed following stimulation with sCP-CM or unconditioned media. Chemotactic activity: We tested the capacity of the sCP-CM (N=4 biological replicates) to induce the migration of sPAECs in a transwell cell-culture system. Endothelial cell basal medium-2 basal medium or endothelial cell basal medium-2 supplemented with 100 ng/mL of swine recombinant VEGF-A were used as controls. In separate assays, an antagonist of Tie2 kinase receptor was used to contrast the effect of sCP-CM on migration. Endothelial proliferation: The capacity of sCPs and sCP-CM (N=4 biological replicates) to promote sPAEC proliferation was assessed by the Click-iT EdU Cell Proliferation Kit for Imaging, Alexa Fluor 488 dye (Thermo Fisher Scientific). sPAECs maintained in unconditioned medium were used as a control.

Dynamic Culture of sCPs on CorMatrix

After completion of the 5-day static culture, sCP-seeded CorMatrix was matured in a 3-dimensional CulturePro Bioreactor (TA Instruments, New Castle, DE, US). Nonseeded CorMatrix was used as control. Seven and 14 days later, the CM was collected, and the conduits were unstitched and cut in 3 pieces as for static culture. Further samples were also taken for mechanical and cell viability studies. The list of reagents and specific use of derived sCP lines in the CorMatrix studies are reported in Table S5.

Characterization of Cellularized CorMatrix Conduits

Histological assessment of the conduit structure: To obtain a general layout of the cell and interstitial collagen distribution within the CorMatrix conduit, frozen sections were stained with hematoxylin and eosin, elastic tissue van Gieson, and Mallory’s trichrome. Viability and apoptosis: After detachment from the CorMatrix conduit by enzymatic digestion, cell viability was determined with trypan blue and apoptosis with ApopTag Red. In addition, cell viability was assessed in situ using a Viability/Cytotoxicity immunofluorescent kit (Thermo Fisher Scientific). Saponin-treated samples were used as positive controls for cell death. Proliferation: After permeabilization, samples were stained with antiswine Ki67 primary antibody (Abcam, Cambridge, UK). Expression of mural cell markers: Sections were incubated with an antiswine neural/glial antigen 2 (NG2) primary antibody or with antihuman α-smooth muscle actin (Sigma-Aldrich, Gillingham, UK), calponin (Abcam), transgelin (Santa Cruz Biotechnology, Peaslake, UK), and smoothelin (Santa Cruz Biotechnology).
and smooth muscle myosin heavy chain (Abcam). Then, secondary antibodies were added on the sections for 1 hour.

**Analysis of collagen secretion:** Levels of soluble collagen 1 in the CM of cellularized conduits were assessed using an antihuman ELISA kit (R&D Systems, Minneapolis, MN, US).

**Mechanical tests of CorMatrix conduits:** Elastic modulus,
maximum tensile stress, and strain at rupture of unseeded and cellularized conduits (N=4 biological replicates) were measured using an Instron 3343 device. A swine left pulmonary artery (LPA) specimen served as control.

**In Vivo Feasibility Study in Piglet Model of LPA Reconstruction**

Two 9-week-old littermate Landrace female piglets, under general anesthesia and neuromuscular blockade, underwent LPA resection to accommodate the conduit (~10 mm long and ~6 mm in diameter), as previously reported and described in detail in Data S1. One piglet received a conduit cellularized with sCPs from a sister piglet and cultured under static (5 days) and dynamic conditions (7 days). The other piglet was implanted with an unseeded conduit. Animals recovered under intense postoperative monitoring for the initial 24 hours. Imaging studies were performed using a 2-dimensional Doppler echocardiography system (VividQ; GE Healthcare, Cardiff, UK) and a cardiac magnetic resonance 3-Tesla scanner (Siemens Healthcare, Erlangen, Germany) at baseline and 4 months after implantation, with further echocardiography at 1, 2, and 3 months postsurgery. Then, swine were euthanized, and the grafted LPA was harvested. Tissue was snap frozen, fresh frozen in optimal cutting temperature compound, or fixed in 4% paraformaldehyde before paraffin inclusion. Sections were used for histology, immunohistochemistry, and morphometric analyses.

**Statistical Analyses**

The Student t test was used when comparing 2 groups and ANOVA with post hoc when comparing >2 groups. Values are expressed as means±SEM or SD. Probability values (P)<0.05 were considered significant. Results from the in vivo feasibility study are reported in a descriptive format.

**Results**

**Immunohistochemical Localization of sCPs**

Multiple target immunohistochemistry was used for cell-type localization in cardiac tissue (Figure 1). CD31pos/CD34pos ECs were typically found around the lumen of capillaries and arterioles. Moreover, we identified CD31neg/CD34pos/NG2pos cells around capillaries (Figure 1A) and especially within the external lamellae of arterioles (Figure 1B).

**Antigenic Profile of Expanded sCPs**

To isolate and generate stocks of sCPs from piglets hearts, we used a modified version of the standard operating procedure previously used on leftovers of CHD reconstructive surgery, the main changes being the substitution of fetal bovine serum with swine heat-inactivated serum (as a constituent of the growth medium) and swine gelatin (as a coating material of culture dishes). For the purpose of the present study, we have successfully isolated and expanded 15 CP lines from pieces of piglet cardiac ventricles as small as 0.01 g in weight (lowest limit of success).

We demonstrated that expanded cells have a typical spindle-shaped morphology (Figure 1C). Cells grew quickly in culture with an average doubling time of 44.5 hours (using fresh cells) and 41.7 hours (using thawed cells). From the initial seeding number (30 000 cells), sCPs reached the final counts of ~600 000 (fresh) and ~500 000 cells.
(thawed) at 8 days of culture (Figure 1D). Viability of expanded cells was consistently >90% in all the samples examined (Figure 1E).

Immunocytochemistry analyses illustrated in Figure 1F and 1G confirmed that expanded cells express the mesenchymal markers, NG2, PDGFRβ (platelet-derived...
growth factor receptor beta), vimentin, and ecto-5-nucleotidase (CD73). Moreover, they were positive for the cardiac transcriptional binding factor, GATA-binding protein 4, and the transcription factors, (sex determining region Y)-box 2 and octamer-binding transcription factor 4, but negative for nanog homeobox (NANOG) and the endothelial markers, vascular endothelial-cadherin and CD31. When looking at markers that identify vascular smooth muscle cells, immunocytochemistry revealed that sCPs express α-SMA and calponin. Moreover, positive expression for Ki67 confirmed their proliferative activity. Using flow cytometry, we demonstrated that, like human CPs, sCPs abundantly express the pericyte marker, PDGFRβ, mesenchymal markers CD105, CD90, CD44, and CD73, while being negative for CD146, CD31, and the hematopoietic marker, CD45 (Figure 1H and 1I). sPAECs (Figure 1J) and peripheral blood mononuclear cells (Figure 1K) were used as positive controls for expression of CD31 and CD146 (endothelial markers) and CD45 and CD11b (hematopoietic markers) in flow cytometry and immunocytochemistry studies.

Clonogenic Potential of Expanded sCPs

Two biological replicates were sorted as single cells and cultured in 96-well plates (Figure 2A). Two weeks later, 4.6% and 9.2% of freshly processed cells formed colonies. The same cell lines underwent the clonogenic assay after a cycle of freezing and thawing. In this experiment, colonies were generated by the 2 cell lines with a frequency of 7.9% and 21.3%, respectively. Of these primary colonies, 2 (0.8%) and 3 (1.3%) from fresh cell lines and 2 (0.8%) and 13 (5.4%) from thawed cell lines could be further expanded in culture. Figure 2B shows that clonogenic cells maintained the original phenotype as assessed by immunocytochemistry.

Angiocrine Properties of Expanded sCPs

qPCR analysis of angiogenic gene transcripts in 5 sCP lines showed that these cells express more VEGF-A and ANG1, but less ANG2, than control sPAECs (Figure 2C). A similar pattern was observed comparing levels of those angiogenic factors in the CM (Figure 2D). In addition, FGF-2 protein levels were remarkably higher in CM of sCPs compared with sPAECs (Figure 2D). This angiocrine profile resembles the described paracrine phenotype of human CPs. Both sCPs (Figure 2E) and their CM (Figure 2F) could enhance the network-forming capacity of sPAECs.

Chemotactic Activity of Expanded sCPs on sPAECs

Next, we examined whether factors secreted by sCPs may exert chemoattractant effects on sPAECs, a property instrumental to the promotion of in vivo endothelialization of the graft. Results of a transwell migration assay, where migrated cells were examined using 4′,6-diamidino-2-phenylindol or Giemsa staining, revealed that sCP-CM increased the rate of sPAEC migration by ∼2-fold compared with endothelial cell basal medium-2 basal medium or endothelial cell basal medium-2 supplemented with VEGF-A (Figure 3A through 3C). Interestingly, the addition of an anti-Tie2 kinase receptor antagonist inhibited the chemotactic effect of sCP-CM, thus suggesting that ANG1 signaling is involved in sPAEC attraction (Figure 3D through 3F).

Proliferation of sPAECs

In addition, we tested whether CPs and their secretome may stimulate sPAEC proliferation (Figure 3G through 3H). Results indicate that the abundance of 5-ethynyl-2′-deoxyuridine—

Figure 3. Continued
positive sPAECs was not increased by coculturing them with sCPs or exposing them to the sCP-CM (72.8±2.6% and 69.6±2.3% versus 66.2±2.3% in sPAECs alone; \( P=0.29 \) for both comparisons). Considering these data in light of the Matrigel and transwell assays results, we speculate that sCPs exert proangiogenic effects through stimulation of sPAECs migration and stabilization of newly formed sPAEC networks, which would be otherwise subjected to spontaneous regression in the Matrigel assay.

**Incorporation of sCPs in a Clinical-Grade Conduit**

Next, we seeded sCPs (20 000 cells/cm²) on CorMatrix, a clinically approved graft material, and cultured the seeded and control unseeded conduits for 5 days under static conditions. In additional experiments, the 2 systems were transferred from the static condition to a flow bioreactor for a period of 1 or 2 weeks of dynamic culture.

Figure 4 shows representative images from the histology and immunohistochemistry analyses performed on conduits harvested at the end of each of the above culture stages. Staining with hematoxylin and eosin documented that seeded cells adhered to the surface of the conduit, forming a thicker layer at 14 days postdynamic culture as compared with poststatic culture (Figure 4A). In seeded conduits, fibers of elastin (van Gieson; Figure 4B) and collagen (azan Mallory; Figure 4C) were clearly detected in proximity of the cell-seeded area and across the matrix, with the collagen signal intensity being stronger as compared with unseeded conduits. A freshly collected swine LPA was used for comparison. The
bar graph shows that there was a progressive increase in collagen content throughout the culture period of the cellularized graft, which peaked at 14 days of the dynamic conditioning in the bioreactor (Figure 4C). At this stage, the initial gap in collagen content between the native CorMatrix and LPA was almost completely abrogated. As expected, soluble collagen was undetectable in the CM of control unseeded CorMatrix. In contrast, secreted soluble collagen averaged 22.4 ± 4.2 ng/mg of protein in the CM collected from cellularized CorMatrix (data not shown). These findings confirm that CPs actively produce ECM proteins (collagen) and maintain this property once incorporated into the conduit.

Next, we verified whether sCPs maintain their original phenotype or acquire additional markers after culture of the conduit under static conditions and subsequent application of flow in the bioreactor. As expected, control unseeded conduits did not show any positive staining for the studied markers, thus confirming these to be acellular. Seeded conduits collected at the end of the static culture showed few NG2-expressing cells, with this antigenic cell phenotype being remarkably more abundant after application of flow, but maintaining the original location at the seeded surface of the conduit (Figure 4D). A similar pattern was observed for the other natively expressed antigens, α-SMA (Figure 4E) and calponin (Figure 4F), whereas cells in the conduits were negative for transgelin, smoothelin, and smooth muscle myosin heavy chain, thus indicating that they did not acquire a mature muscular phenotype with transfer from plastic into the conduit (data not shown).

Viability was assessed in situ with a viability/cytotoxicity immunofluorescence kit as well as using trypan blue after cell detachment from the matrix, using trypsin or accutase, and cell cytospin. Positive controls were treated with saponin or H2O2. Cells showed a consistently high viability (>90%) in situ and after detachment with both enzymatic methods and length of conditioning time (Figure 5A and 5B). Results of terminal deoxynucleotidyl transferase dUTP nick end labeling assays documented low apoptosis levels.
Figure 5. Cell viability and proliferation of CorMatrix grafts engineered with swine cardiac pericytes. 

A, High viability of sCPs detached from the matrix using 2 enzymatic methods at the end of static and dynamic culture. 

B, The data were confirmed using Calcein staining of the grafts. Saponin was used as a control cytotoxic agent. 

C and D, Apoptosis was assessed by the TUNEL assay. Bar graph showing results (C) and representative microscopic images displayed as single and merged channels of 2 different fields in the same sample (i–ii, blue=DAPI; red=TUNEL; merge=DAPI/TUNEL) (D). Data are mean±SEM of 4 biological replicates. 

E, Representative images of proliferation assessed by Ki67 staining. Fluorescent images are displayed as single and merged channels. No staining was detected in unseeded grafts in the different experimental conditions. 

F, Graphs showing proliferation following static and dynamic conditions. BF indicates bright field; DAPI, 4',6-diamidin-2-fenilindolo; PD, postdynamic; PS, poststatic; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; +ve control, positive control.
(<7%; Figure 5C and 5D). Quantitative analysis of cell proliferation revealed that 8.9±8.0% of total cells expressed Ki67 at 5 days of static culture. Frequency of proliferating cells decreased following dynamic culture (5.4±1.0% and 2.1±1.4% Ki67-positive cells at 7 and 14 days, respectively; Figure 5E and 5F). However, because of large variability of the measure, the change in proliferation did not reach statistical significance.

Mechanical Properties of Conduits Engineered With sCPs

Seeded and unseeded conduits (4 biological replicates, each one with 3 internal replicates) were tested after 7 and 14 days of maturation in the bioreactor. Representative curves and cumulative data of the relation between stress and strain are reported in Figure 6 and Table 1. Analysis of tensile tests at day 7 displayed a 1.8-fold reduction in maximum stress for seeded conduits compared with the unseeded ones (P<0.05), whereas strain at breaking point and Young’s modulus did not differ between groups. The conditioning period of 14 days showed a significant decrease in stiffness, demonstrated by the reduction of Young’s modulus (1.7-fold versus unseeded; P<0.05) and an increase in strain at maximum load (1.2-fold versus unseeded; P<0.05), whereas there was no difference in maximum stress. Thus, cellularization reduced the mechanical mismatch between native CorMatrix and LPA, supporting the feasibility of implantation with a lower risk of failure.

In Vivo Feasibility Study

Finally, we performed a feasibility study where two 4-week-old sister weaner piglets underwent LPA surgical replacement with seeded or unseeded CorMatrix conduits, respectively. Both animals survived the experimental period and showed similar growing curves.

- LPA imaging

Figure 7 shows representative images of Doppler and cardiac magnetic resonance, which confirm the patency of grafted LPA in both piglets transplanted with seeded or unseeded grafts. Table 2 reports the individual blood flow velocity at different times of follow-up, with values within the normal range for both animals.

- Histological analysis of native PA and implanted grafts

Hematoxylin and eosin images show extensive nucleation throughout the structure of the proximal and distal seeded graft (Figure 8A). In both seeded and unseeded grafts, there were minimal levels of calcification, as assessed using von Kossa staining (Figure 8B). Elastin is a major component of the PA. In line with this, van Gieson staining displayed a consistent layer of organized elastin in the native tissue of the LPA (Figure 8C). Elastin deposits were visible in the seeded graft attached to the proximal and distal LPA, but less defined in the unseeded graft (Figure 8C). Collagen fibers (both interstitial and perivascular) were detected especially in the unseeded explant, probably attributable to the formation of a fibrous scarred tissue. In addition, new muscle tissue appeared in the LPA and in the perivascular area of the explants (Figure 8D). The immunohistochemical analysis showed an organized multilayer of smooth muscle cells populating the tunica media of the LPA. Endothelial cells identified by the CD31 marker were present at the luminal side of the artery and in vessels within the adventitia (Figure 8E). Cells expressing NG2 were also found in the

Table 1. Mechanical Properties of CorMatrix Grafts and Swine LPA

| Conditioning Period | Samples | Young’s Modulus (MPa) | Maximum Stress (MPa) | Strain at Rupture (%) |
|---------------------|---------|-----------------------|----------------------|-----------------------|
| 7 days              | Unseeded| 17.7±2.1              | 4.2±0.5              | 55±6                  |
|                     | Seeded  | 13.2±2.6              | 2.4±0.3*             | 56±4                  |
| 14 days             | Unseeded| 15.5±2.1              | 4.2±0.6              | 69±1                  |
|                     | Seeded  | 8.9±1.5*              | 3.1±0.7              | 83±4*†                |
| LPA                 |         | 0.55±0.07             | 0.28±0.09            | 151±12                |

Values are means±SE, N=4 biological replicates, each one with 3 internal replicates. LPA indicates left pulmonary artery.

*P<0.05 vs unseeded grafts within each time point; †P<0.01 vs corresponding group (seeded or unseeded) harvested at 7 days of conditioning in the bioreactor.
adventitia of the vessels. Notably, more organized vessel structures appeared in seeded graft adventitia compared with unseeded ones (Figure 8E). Positive staining controls, used in association with main histological analyses of grafts, are shown in Figure 8F.

Discussion

Cell therapy and tissue engineering are gaining momentum for correction of congenital heart defects. Preclinical studies have demonstrated the utility of delivering different cell types, including skeletal myoblasts, cord blood stem cells, and mesenchymal stromal cells, either intramyo- or epicardially to treat right ventricle dysfunction and pulmonary artery hypertension induced by pressure or volume overload. This experimental evidence was followed by clinical trials, some already concluded and others still ongoing, in patients with hypoplastic left heart syndrome reviewed in a previous work. A more-complex endeavor aims to create cellularized conduits to correct severe cardiac defects, such as tetralogy of Fallot, which are characterized by a constriction of the right ventricle outflow tract and PA. Initial evidence indicates that acellular grafts repopulated with ECs or bone marrow cells are less susceptible to thrombosis or obstruction. We recently developed an alternative approach where a swine small intestinal submucosa graft functionalized with umbilical mesenchymal stromal cell-derived vascular smooth muscle cells was used for replacement of the PA in piglets. After 6 months from implantation, grafted arteries had developed a functional intima and media without evidence of aneurism formation. Using a similar strategy, we have now demonstrated the feasibility of using CPs to generate living vascular conduits for reconstruction of the PA. The 2 approaches are mutually compatible and adaptable to the individual clinical condition and time of diagnosis. Fetal cell or umbilical cord stem cells isolated at the time of birth could be used if CHD is diagnosed prenatally. When diagnosis of CHD is made after birth or in babies who require a palliative intervention soon after birth, tissue-specific cardiac cells, such as CPs, could be isolated from surgical cardiac leftovers to generate living conduits to be implanted at the occasion of the definitive correction.

Human pericytes represent the cell product to be ideally tested in preclinical safety/efficacy studies before a first-in-human clinical trial. However, their use in a xenogeneic piglet model is discouraged because of the adverse effects and confounding influence of immunosuppression to prevent rejection. These concerns are particularly serious considering the need for chronic immunosuppression to be started in young developing animals. Therefore, the use of a swine
An appropriate in vivo model to assess feasibility and efficacy of the cell-engineered CorMatrix conduit. Pericytes signal to ECs through the binding of ANG1 to Tie2, resulting in activation of pathways mediating proliferation, migration, and anti-inflammatory signals. Using a Tie2 antagonist, here we demonstrated that this signaling is instrumental to the recruitment of ECs by the sCP secretome. Our data indicate that sCPs promote the organization of sPAECs on Matrigel, likely through activation of migration and inhibition of degradation. This is in line with the well-known role of pericytes acting as vascular stabilizers of nascent vascularization.

The use of ECM as a biological scaffold for tissue repair and regeneration is an established procedure within the clinical community. Commercial scaffolds manufactured from a range of ECM materials from different animals are available for use in cardiac surgery. CorMatrix, the most used product of this type, is a decellularized porcine small intestinal submucosa product that has received approval by both the US Food and Drug Administration and European authorities for cardiovascular applications. A recent meta-analysis assessing the results of clinical studies using CorMatrix in pediatric populations indicates favorable outcomes. However, some of the claimed advantages of the material, such as the bioinductive capacity to support the ingrowth of reparative cells from the host without inducing inflammatory reactions, have been questioned by several reports. Histological examination of failing grafts showed moderate-to-severe grade inflammation in the explant tissue without signs of regeneration or integration. Interestingly, these reactions were not observed in swine models, thus suggesting the possibility that inflammation was a reaction to antigenic epitopes present in the swine intestine, but not in humans. Moreover, 90% of the CorMatrix is made of collagen type I, but contains little amounts of elastin, which is instead a major component of a pulmonary artery and a determinant in maintaining vascular hemodynamic efficiency.

Recellularization with stromal cells before in vivo implantation could overcome the inadequate constructive remodeling capacity and lack of elasticity of the native cross-linked CorMatrix. Confirming the data of our previous study on human pericytes, the present report shows that sCPs proliferate and engrain onto the external surface of CorMatrix, maintaining a high degree of viability and the original antigenic phenotype. This is in keeping with the goal to create a cellularized adventitial layer, from which, upon in vivo implantation, sCPs could exert paracrine recruiting effects on the recipient’s cells and timely remodeling of the matrix. The lack of sCP penetration into the matrix core before in vivo implantation is, in our opinion, a positive outcome. In fact, for sCPs to infiltrate the internal layer of the conduit, the matrix should undergo degradation. This might result in making the conduit unable to withstand the mechanical forces in vivo. The equilibrium between breakdown of the structure attributed to proteases and production of ECM proteins plays a fundamental role in the stabilization and rearrangement of the graft as well as native blood vessel. Our results indicate that collagen content progressively increased in sCP-seeded grafts throughout the maturation in the bioreactor. Collagen possesses useful mechanical properties that can confer the CorMatrix with increased elasticity and greater extensibility before fracture. In line with the above, mechanical tests at different times of the in vitro maturation process demonstrated that CorMatrix conduits acquired a more elastic behavior when seeded with sCPs, as denoted by a significant decrease in Young’s modulus, but also an increased strain at rupture. Similar mechanical effects were

### Table 2. Blood Flow Velocity Measured by Doppler

|          | Unseeded | Seeded |
|----------|----------|--------|
| LPA      |          |        |
| Preop    | 0.86     | 1.23   |
| Postop   | 0.80     | 1.41   |
| RPA      |          |        |
| Preop    | 1.33     | 0.93   |
| Postop   | 0.89     | 1.26   |
| MPA      |          |        |
| Preop    | 1.04     | 1.33   |
| Postop   | 1.12     | 1.35   |

Values are mL/sec. LPA indicates left pulmonary artery; MPA, main pulmonary artery; RPA, right pulmonary artery; Postop, postoperation; Preop, preoperation.
Figure 8. Analyses of the explanted grafts. A, H&E staining of unseeded and seeded grafts. B, Von Kossa staining. C, Von Gieson staining. D, Collagen staining. E, Immunohistochemistry of LPA and explanted grafts. Cells expressing α-SMA (red) and CD31 (white) are present in the internal layer and luminal site of the native tissue and graft. In addition, NG2-positive cells (green) were identified in the adventitia around the vasa vasorum. F, Positive control tissues for immunohistochemistry graft comparison. Swine saphenous vein showing H&E (i) and EVG staining (ii, cells and elastic fibers, respectively). Swine MI heart biopsy displaying Azan Mallory staining (collagen) in the remote area (iii). Aortic valve from swine MI model showing Von Kossa staining for identification of microcalcifications (iv). Swine health cardiac tissue stained with Ki67 for cell proliferation (v). ADV and PA indicate adventitia and pulmonary artery (yellow color); CD, cluster of differentiation; COL, collagen; DAPI, 4',6-diamidino-2-phenilindolo; EVG, elastic fibers Van Giesons'; H+E, hematoxylin and eosin; LPA, left pulmonary artery; MI, myocardial infarction; NG2, neural/glial antigen 2; SMA, smooth muscle actin.
reported by Sodian et al in a study using tissue-engineered trileaflet heart valves.\textsuperscript{26}

The in vivo study provided us with valuable data in preparation of a properly designed efficacy trial, but also highlighted the strengths and weaknesses of the swine model. We used Doppler and cardiac magnetic resonance imaging to measure blood flow velocity and confirm the patency of the implanted graft. The values of blood flow velocity from the present study are consistent with a previous report.\textsuperscript{11} A power calculation based on combined data from the 2 studies indicate that a minimum of 7 animals per group would be necessary to detect a difference of 0.3 mL/min with an SD of 0.2. Our previous study confirmed that graft stenosis is a rare event in swine compared with humans,\textsuperscript{11} possibly attributable, as mentioned above, to a lower inflammatory reaction to a product from the same species. Therefore, hemodynamic outcomes should be considered in combination with histological outcomes, such as matrix remodeling, endothelialization of the intima, and cellularization of the media and adventitia, as shown in the present report.

**Conclusions**

We demonstrated that sCPs can be used as a cell surrogate of human CPs to engineer CorMatrix conduits implantable in the piglet’s LPA. A controlled randomized efficacy/safety study based on this technology is currently ongoing with provision to be completed by March 2020. The completion of the full study would provide clear evidence of the advantage of using pericytes-engineered conduits over the unseeded CorMatrix, in terms of...
structural and functional performance. This novel approach, using cells extracted from small pieces of cardiac tissue available during palliative surgery, may open new avenues for correction of congenital cardiac defects with remarkable medical and social benefits.

Acknowledgments
Author Contributions: Madeddu, Caputo, and Ghorbel conceived and designed the research. Alvino, Thomas, Kilcooley, Fagnano, Cathery, Avolio, Ghorbel, Iacobazzi, and Carrabba performed experiments and analyzed data. Alvino drafted the manuscript. Madeddu and Caputo were responsible as corresponding authors of the final writing. All authors read and approved the final manuscript.

Sources of Funding
This study was supported by grants from the Sir Jules Thorn Charitable Trust (Caputo, Madeddu), the Enid Linder Foundation (Caputo, Ghorbel), the British Heart Foundation (Caputo), the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre in Cardiovascular Medicine (Caputo), and the Medical Research Council (Madeddu, Caputo, Ghorbel).

Disclosures
None.

References
1. Khoshnood B, Lelong N, Houyel L, Thieulin AC, Jouannic JM, Magnier S, Delezoide AL, Magny JF, Rambaud C, Bonnet D, Goffinet F; EPICARD Study Group. Prevalence, timing of diagnosis and mortality of newborns with congenital heart defects: a population-based study. Heart. 2012;98:1667–1673.
2. Tennant PW, Pearce MS, Bythell M, Rankin J. 20-year survival of children born with congenital anomalies: a population-based study. Lancet. 2010;375:649–656.
3. Avolio E, Rodriguez-Araolaza I, Spencer HL, Riu F, Mangialardi G, Slater SC, Rowlinson J, Alivon VV, Idowu OO, Soyombo S, Okawa A, Swim MM, Kong CH, Cheng H, Jia H, Ghorbel MT, Hancock JC, Orchard CH, Angelini G, Emanueli C, Caputo M, Madeddu P. Expansion and characterization of neonatal cardiac pericytes provides a novel cellular option for tissue engineering in congenital heart disease. J Am Heart Assoc. 2015;4:e002043. DOI: 10.1161/JAHA.115.002043.
4. Hibino N, McGillicuddy E, Matsuruma G, Ichihara Y, Naito Y, Breuer C, Shinoka T. Late-term results of tissue-engineered vascular grafts in humans. J Thorac Cardiovasc Surg. 2010;139:431–436.
5. Cebotari S, Todorache I, Schilling T, Haverich A. Heart valve and myocardial tissue engineering. Herz. 2010;35:334–341.
6. Dohmen PM, Lembove C, Holinski S, Pruss A, Konertz W. Ten years of clinical results with a tissue-engineered pulmonary valve. Ann Thorac Surg. 2011;92:1308–1314.
7. Pan H, Gazarian A, Buff S, Solla F, Gagnieu MC, Leveneur O, Watrelot-Virieux D, Morisset S, Sobh M, Michallet MC, Roger T, Dubernard JM, Michallet M. Oral cyclosporine A in neonatal swine for transplantation studies. Immunopharmacol Immunotoxicol. 2015;37:19–25.
8. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis. 2000;35:333–346.
9. Breuer O, Schultz A. Side effects of medications used to treat childhood interstitial lung disease. Paediatr Respir Rev. 2018;26:68–79.
10. Kilkeny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8:e1000412.
11. Ghorbel MT, Jia H, Swim MM, Iacobazzi D, Albertario A, Zebbe C, Holopherne-Doran D, Hollander A, Madeddu P, Caputo M. Reconstruction of the pulmonary artery by a novel biodegradable conduit engineered with perinatal stem cell-derived vascular smooth muscle cells enables physiological vascular growth in a large animal model of congenital heart disease. Biomaterials. 2019;217:119284.
12. Wehman B, Kaushal S. The emergence of stem cell therapy for patients with congenital heart disease. Circ Res. 2015;116:566–569.
13. Tsilimigras DI, Okonkwo EM, Moris D, Schizas D, Economopoulos KP, Mylonas KS. Stem cell therapy for congenital heart disease: a systematic review. Circulation. 2017;136:2373–2385.
14. Avolio E, Caputo M, Madeddu P. Stem cell therapy and tissue engineering for correction of congenital heart disease. Front Cell Dev Biol. 2015;3:39.
15. Hoashi T, Matsumiya Y, Miyagawa S, Ichikawa H, Ueno T, Ono S, Saito A, Shimizu T, Okano T, Kawaguchi N, Matsuura N, Sawa Y. Skeletal myoblast sheet transplantation improves the diastolic function of a pressure-overloaded right heart. J Thorac Cardiovasc Surg. 2009;138:460–467.
16. Davies B, Elwood NJ, Li S, Cullinane F, Edwards GA, Newgreen DF, Brizard T. Late-term results of tissue-engineered vascular grafts in humans. Ann Thorac Surg. 2010;89:585–593.
17. Wehman B, Sharma S, Pietris N, Mishra R, Siddiqui O, Bigham G, Aiello E, Murthi S, Pittenger M, Griffith B, Kaushal S. Mesenchymal stem cells preserve neonatal right ventricular function in a porcine model of ventricular overload. Ann J Physiol Heart Circ Physiol. 2011;301:H1816–H1826.
18. Ambasth C, Bittle GJ, Morales D, Parchment N, Saha P, Mishra R, Sharma S, Vasilenko A, Gunasekaran M, Al-Suqi MT, Li D, Yang P, Kaushal S. Regenerative medicine therapy for single ventricle congenital heart disease. Transl Pediatr. 2018;7:176–187.
19. Mosala Nezhad Z, Poncelet A, de Kerchove L, Gianello P, Fervaille C, El Khoury G. Early and mid-term clinical experience with extracellular matrix scaffold for congenital cardiac and vascular reconstructive surgery: a multicentric Italian study. Interact Cardiovasc Thorac Surg. 2015;21:40–49; discussion, 49.
20. Zaidi AH, Nathan M, Emami S, Baird C, del Nido PJ, Gauvreau K, Harris M, Sanders SP, Padera RF. Preliminary experience with porcine intestinal submucosa (CorMatrix) implants in pediatric cardiac patients: a single-center experience. Ann Thorac Surg. 2015;99:1373–1377.
21. Badyak SF, Freytes DO, Gilbert TW. Extracellular matrix as a biological scaffold material: structure and function. Acta Biomater. 2009;5:1–13.
22. Lammers SR, Kao PH, Oi HJ, Hunter K, Lanning C, Albiez J, Hofmeister S, Mecham R, Stenmark KR, Shandas R. Changes in the structure-function relationship of elastin and its impact on the proximal pulmonary arterial mechanics of hypertensive calves. Am J Physiol Heart Circ Physiol. 2008;295:H1451–H1459.
23. Heydarkhan-Hagvall S, Esguerra M, Helenius G, Soderberg R, Johansson BR, Wernstedt C. Normal and disease-specific gene expression in small intestinal submucosa extracellular matrix (CorMatrix(R)) in cardiovascular surgery: a systematic review. Interact Cardiovasc Thorac Surg. 2016;22:839–850.
24. Padalino MA, Quarti A, Angeli E, Frigo AC, Vida VL, Pozzi M, Gargiulo G, Stellin G. Early and mid-term clinical experience with extracellular matrix scaffold for congenital cardiac and vascular reconstructive surgery: a multicentric Italian study. Interact Cardiovasc Thorac Surg. 2015;21:40–49; discussion, 49.
25. Rosario-Quinones F, Magid MS, Yau J, Pawale A, Nguyen K. Tissue reaction to porcine intestinal Submucosa (CorMatrix) implants in pediatric cardiac patients: a single-center experience. Ann Thorac Surg. 2015;99:1373–1377.
26. Badyak SF, Freytes DO, Gilbert TW. Extracellular matrix as a biological scaffold material: structure and function. Acta Biomater. 2009;5:1–13.
Supplemental Material
Data S1.

Harvesting and processing of cardiac tissue
Four-weeks-old Large white/Landrace piglets (UK registered breeder) were euthanized with Euthatal, and heart samples were harvested for in situ identification and isolation/expansion of swine cardiac pericytes (sCPs) (Table S1). Peripheral blood was collected via an indwelling jugular vein cannula for isolation of peripheral blood mononuclear cells (PBMCs) and extraction of serum to be used for sCP expansion. In some experiments, commercial swine heat-inactivated serum (Sigma-Aldrich, UK) was used in alternative to the piglet serum.

In situ immunohistochemistry of sCPs
Cardiac tissue samples were collected and fixed in 4% (w/v) PFA (Sigma-Aldrich, UK) for 16 hours, at +4°C. After one wash in 1x Phosphate Buffered saline (PBS), fixed samples were placed in 30% (w/v) Sucrose for 48 hours, at +4°C, and embedded in OCT (O.C.T. Compound, VWR, UK, cat n: 361603E). Eight-micron sections were cut and fixed in ice-cold glacial Acetone (Fisher, UK) for 5 min, at -20°C. After fixation, sections were kept air-dried for 20 min and hydrated in 1x PBS. 0.01% (v/v) Triton X-100 (Sigma-Aldrich, UK) was used for the membrane permeabilization for 10 min, at RT. Non-specific binding sites were blocked using 5% (v/v), foetal bovine serum (FBS, Life Technologies, UK) in 1x PBS as blocking solution. Double staining combinations of anti-swine NG2/anti-human CD31 and anti-swine CD34/anti-human CD31 primary antibodies were used. After a 16-hour incubation at +4°C, sections were washed in 1xPBS, and secondary antibodies were incubated on the sections for 1 hour, at RT, in the dark (Table S2). The nuclei were counterstained with DAPI (Sigma-Aldrich). The slides were mounted using Fluoromount-G® mounting media (Sigma-Aldrich) and immunofluorescent images were taken using x10, x20 objectives of Zeiss Observer.Z1 microscope (Carl Zeiss Microscopy, LLC, US) and Zen pro software.

CP isolation and expansion
Cardiac samples were processed using a modification of the GMP-compliant standard operating procedure (SOP) previously employed for isolation/expansion and characterization of CPs from the neonatal human heart. Briefly, single cell suspensions of immunomagnetically-sorted CD31-CD34+ cells were cultured onto dishes coated with 1% (w/v) swine gelatin (Sigma-Aldrich) containing Endothelial Cell Growth medium-2 (EGM-2, Promocell, UK) supplemented with 10% (v/v) heat-inactivated swine serum (Sigma-Aldrich), and 1% (v/v) Penicillin and Streptomycin (Pen/Strep). Once reached 80-90% confluence, primary colonies were passaged to new culture dishes. At P2, cells were split for further expansion or generation of frozen stocks.

Assessment of sCP characteristics
• Immunocytochemistry
Expanded cells (N=7 biological replicates run in triplicate) were fixed with freshly prepared 4% (w/v) PFA in 1x PBS for 10 min at +4°C, washed with 1x PBS and probed with the indicated antibodies (Table S2). For detection of intracellular antigens, cells were permeabilized for 10 min at +4°C with 0.1% (v/v) Triton X-100 (Sigma-Aldrich) diluted in 1x PBS. Cells were incubated with the indicated primary antibodies (16 hours at +4°C) and appropriate secondary antibodies (1:200 anti-rabbit Alexa 488 or 1:200 anti-mouse Alexa 488, 1 hour at +20°C in the dark). The nuclei were counterstained with DAPI (Sigma-Aldrich). Slides were mounted using Fluoromount-G (Sigma-Aldrich). Cells were analyzed at a 200X and 400X magnification. Zeiss Observer.Z1 and Zen pro software were utilized to compose and overlay the images. Swine Pulmonary Artery Endothelial Cells (sPAECs, AMSBio, USA) were used as positive controls for endothelial markers.
Flow cytometry

Cells (1x10^6, N=3 biological replicates) were washed in 1X DPBS (Life Technologies) and treated with 1x trypsin/EDTA (Life Technologies). Then, they were washed, spun at 400g for 10 min at +4°C and re-suspended in FACS-staining buffer containing 0.1% (w/v) BSA, 1mM EDTA and 0.1% (v/v) sodium azide, followed by blocking of unspecific binding with 10% (w/v) BSA in 1X DPBS. Next, 2x10^5 cells/tube were incubated with antibodies for 30 min at +4°C, in the dark (Table S3). For detection of the endothelial marker CD31, cells were washed twice in FACS buffer. The flow cytometry procedure included Fluorescence Minus One (FMO) controls. sPAECs were used to verify the expression of endothelial antigens. In addition, we used the Fixable Viability Dye eFluor 780 (eBioscience, UK) to label dead cells and exclude them from the gating strategy. Prior to sample acquisition, the cells were fixed with 1% (v/v) PFA in 1x PBS.

Clonogenic assay:

The test was performed on two sCP lines at P3, using a motorized device connected to the flow cytometric sorter (Cyclone, Beckman Coulter, US). Sorted cells were placed into each well of a 96-well culture plate (Greiner Bio-one, UK) and cultured up to 4 weeks in EGM-2 for quantification of colonies generated from a single cell. A comparative assay between fresh and frozen-thawed sCPs was performed to assess if both conditions allow the generation of clones.

Quantitative PCR of angiogenic factors

Total RNA was obtained from cultured sCPs (miRNeasy mini kit, Cat n: 217004, Qiagen) and reverse-transcribed using a High Capacity RNA-to-cDNA Kit (Cat n: 4387406, Life Technologies). The reverse transcription–PCR was performed using the first-strand cDNA with TaqMan Fast Universal PCR Master Mix (Cat n: 4324018, Life Technologies) and on a Quant Studio 6 Flex Real-Time PCR system (Applied Biosystems) for the genes specified in Table S4.

Secretion of angiogenic factors

Dedicated anti-human ELISA kits were used to measure the immunoreactive levels of Vascular Endothelial Growth Factor-A (VEGF-A), Angiopoietin 1 (ANG 1), Angiopoietin 2 (ANG 2), and basic Fibroblast Growth Factor (bFGF) proteins in conditioned media (CM) from sCPs, which were cultured for 48 hours in 2.5 mL serum-free, endothelial basal medium 2 (EBM-2) under normoxia. All the ELISA kits were from R&D System (cat n: 4324018, Life Technologies) and on a Quant Studio 6 Flex Real-Time PCR system (Applied Biosystems) for the genes specified in Table S4.

Endothelial network formation

The capacity of cells to form networks on Matrigel was assessed using sCPs or sPAECs alone or both in coculture. In addition, the network formation capacity of sPAECs was assessed following stimulation with sCP-CM or unconditioned media (UCM). First, sCPs were labelled with the long-term cell tracker Dil (Thermo Fisher cat n: C7001). Cells were seeded on top of 70 μL thick-coated Matrigel (BD Biosciences) in EGM2 for 6 hours. Images were taken under bright field at 5× and the length of the networks was measured.

Chemotactic activity

Here, we tested the capacity of the sCP-CM to induce the migration of sPAECs. The latter were seeded on transwell cell culture inserts equipped with 8 μm pore size polycarbonate membranes (Corning, cat n: 3422) in EBM-2 basal medium. The migration of sPAECs was stimulated by adding 500 μL of sCP-CM to the bottom of the same wells. In parallel, EBM-2 basal medium or EBM-2 supplemented with 100 ng/mL of swine recombinant VEGF-A (Cambridge Bioscience, cat n: RP0403S-005) were used to assess spontaneous and growth factor directed migration. In separate assays, an antagonist of Tie-2 kinase receptor (Abcam, cat n: 141270) was used to contrast the effect of the sCP-CM on migration. After 16-hour incubation at +37°C, the polycarbonate membranes were washed and scraped with a cotton swab to remove non-migrating cells. Migrated cells at the bottom side of the filter were assessed by GIEMSA and DAPI. For GIEMSA staining,
the membranes were fixed in 4% (w/v) PFA and 100% (v/v) Methanol. GIEMSA stain solution was added for 60 min at RT, protected from light. For staining of nuclei, the membranes were washed in 4% (w/v) PFA and incubated with 1:1000 DAPI for 2 min at RT. In either case, membranes were washed twice and gently removed from the inserts with a scalpel for the visualization of the cells and nuclei, respectively. Membranes were analyzed with an epifluorescence microscope at ×200 magnification; 10 fields were randomly acquired, and cells counted. Migrated cells were expressed as a percentage of total seeded cells.

- **Endothelial cell proliferation**

The capacity of sPAECs to proliferate in the presence of sCPs and sCP-CM was assessed by Click-iT™ EdU (5-ethynyl-2'-deoxyuridine) Cell Proliferation Kit for Imaging, Alexa Fluor™ 488 dye (Thermo fisher, cat n: C10337) using UCM and sCP-CM media. Briefly, sCPs were labelled with Dil according the manufacturer’s instructions prior to seeding for the assay. Swine PAECs and sCPs were seeded into plastic dishes and the EdU was incubated for a minimum of 16 hours with EBM-2 and sCP-CM. Cells were fixed in 4% (w/v) PFA and the membrane were permeabilized using 0.1% (v/v) Triton X-100. The EdU detection reagents were added to the wells for 30 minutes and an anti-swine CD31 primary antibody (Abcam cat n: ab28364) was incubated overnight, at +4 °C, protected from light. A secondary antibody was used to detect sPAECs stained with CD31 antigen. Cells were incubated with 1:10,000 HOECHST for 3 minutes, at +21 °C, protected from light. Fluorescent images were taken with a fluorescent microscope and 10 fields were acquired randomly using 20X magnification objective. Proliferative sPAECs were counted as a percentage of total sPAECs seeded.

**Studies on cellularized CorMatrix**

- **Static culture of sCPs on CorMatrix**

Pieces of CorMatrix® ECM® (CorMatrix Cardiovascular, Sunnyvale, CA) were cut, firmly positioned at the bottom of wells of a 48-well plate using Cell Crown inserts (Sigma-Aldrich), and primed with EGM-2 media for 48 hours. Next, sCPs (P5, 20,000/cm²) were seeded into each CorMatrix-containing well and cultured for 5 days. The CM was then collected and the CorMatrix samples were cut in three pieces: one was fixed in 4% (w/v) PFA for 16 hours at +4°C and embedded in paraffin for histological studies, while the other two pieces were OCT-frozen for molecular biology analyses. Eight biological replicates were examined unless differently specified.

- **Dynamic culture of sCPs on CorMatrix**

After completion of the 5-day static culture, sCP-seeded CorMatrix was further grown in a 3D CulturePro™ Bioreactor (TA instruments, USA). Non-seeded CorMatrix was used as control. The conduit was stitched on the rotating arm to fashion a tube shape through the centre of which runs the rotating arm. The bioreactor was filled with EGM-2 media supplemented with 10% (v/v) swine serum and 1% (v/v) Pen/Strep and maintained in the incubator at +37°C. Seven and fourteen days later, the CM were collected, and the conduits were unstitched and cut in three pieces: one was fixed in 4% (w/v) PFA for 16 hours at +4°C and embedded in paraffin, and the two other pieces were frozen for OCT-embedding and for RNA and protein analysis. Four biological replicates were examined unless otherwise specified. The list of swine and specific experimental usage of derived sCP lines in the CorMatrix studies is reported in Table S5.

- **Characterization of cellularized CorMatrix grafts**

**Histological assessment of the graft structure:** To obtain a general layout of the cells, elastin, and interstitial collagen distribution within the CorMatrix grafts, frozen sections were stained with Haematoxylin and Eosin (H&E), Elastic tissue-Van Gieson’s (EVG), and Mallory’s trichrome using a Shandon Varistain 24-4 slide stainer (Thermofisher, UK) on slides mounted with DPX (Sigma-Aldrich) and covered with cover slips. Images were acquired using Zeiss Axio
Collagen deposits onto grafts were quantified as percentage of total area using ImageJ software. **Viability and apoptosis:** Cells were detached from the CorMatrix graft by enzymatic digestion and cytospun for 5 min at 500 rpm at RT onto histology slides using an EZ double cytofunnelTM (Thermofisher, UK cat n: A78710005) and a cytospin machine (Cytospin 4, Thermofisher, UK). Two different enzymes (Trypsin and Accutase) were used for cell detachment. Viability was determined with Trypan blue and apoptosis with Apoptag Red In situ Apoptosis Detection Kit (Millipore, UK cat n: S7165). As a positive control for apoptosis, sCPs were treated with 15 µm H2O2 (Sigma, UK cat n: H1009) for 1 hour at +37°C. In addition, cell viability was assessed in situ (without detaching cells from the graft) at 5 days post-static and 7 days post-dynamic culture using a Viability/Cytotoxicity immunofluorescent kit (Thermofisher, UK, cat n: L3224). Saponin (Sigma-Aldrich) treated samples were used as positive controls. Grafts were imaged using Zeiss microscope. **Proliferation:** After permeabilization with 0.1% (v/v) Triton X-100, samples were stained with anti-swine Ki67 primary antibody (Abcam, UK, cat n#: ab15580). **Expression of mural cell markers:** Here, we determined the effect of engraftment on the expression of pericyte and Vascular Smooth Muscle Cell (VSMC) markers. Eight-micron sections from frozen samples were cut and fixed in ice-cold glacial Acetone (Thermofisher) for 5 min at -20°C. After fixation, sections were kept air-dried for 20 min and hydrated in 1x PBS. Non-specific binding sites were blocked using 5% (v/v) foetal bovine serum (FBS Life Technologies, UK) or 10% (v/v) Normal Goat serum (NGS, Life Technologies) in 1x PBS as blocking solution. Sections were incubated for 16 hours, at +4°C, with an anti-swine NG2 primary antibody or with anti-human and anti-swine α-Smooth Muscle Actin (α-SMA, Sigma, UK), Calponin (CALP, Abcam, UK), Transgelin (TAGLN, Santa-Cruz, UK), Smoothelin (SMTN, Santa Cruz, UK), and Smooth Muscle Myosin Heavy Chain (SMMHC, Abcam, UK). Secondary antibodies were incubated on the sections for 1 hour, at RT, protected from the light. The nuclei were counterstained with DAPI. The slides were mounted using Fluoromount-G® mounting media (Sigma-Aldrich) and immunofluorescent and brightfield images were taken using x2.5, x10, x20 objectives of Zeiss microscope. **Analysis of collagen secretion by CorMatrix grafts:** The CM of cellularized grafts (collected after culture under static or dynamic conditions) were centrifuged at 400 g for 10 min at RT to assess the levels of soluble Collagen 1 (COLIA1) using an anti-human COLIA1 ELISA kit (R&D Systems, cat n: DY6220-05). The OD value was measured using a microplate reader set to 450 nm. **Mechanical tests of CorMatrix grafts:** The elastic modulus, maximum tensile stress and strain at rupture were measured using an Instron 3343 device (Illinois Tool Works Inc., USA). The study was conducted on unseeded and cellularized grafts (N=3 biological replicates) and a swine Left Pulmonary Artery (LPA) specimen serving as control. In detail, CorMatrix tubular structures, seeded and unseeded, were opened along the stitches and cut to obtain a rectangular-shaped sample with length of 20±5mm, width of 6.5±0.35mm and thickness of 3.5±0.15mm. Tests were performed at +37°C in PBS, the distance between the two clamps was set to 10±1mm and specimens were subjected to strain rate of 0.01 min⁻¹ until failure. Stress–strain curves of grafts and swine LPA (control) were derived from the load–elongation data. **In vivo study assessing the feasibility of implanting a cellularized graft conduit in piglet LPA** Surgical procedures were performed with swine under general anesthesia (Ketamine/Midazolam/Dexmedetomidine, Isoflurane) and neuromuscular blockade (Pancuronium Bromide). Details of the operation have been reported previously. Briefly, a left posterolateral thoracotomy was performed in two 4-week-old sister Landrace female piglets. The proximal and distal part of the LPA (just before the upper and middle lobe branches of the LPA)
was clamped and a 3–4 mm of the LPA was resected to accommodate the conduit-shaped graft (~10 mm long and ~6 mm diameter). One piglet received a conduit cellularized with sCPs from a sister piglet and cultured under static (5 days) and dynamic condition (7 days). The other piglet was implanted with an unseeded conduit. Animals recovered under intense postoperative monitoring for the initial 24 hours. Analgesic (Paracetamol, Morphine) and antibiotics (Cefuroxime) were administered during this period according to the needs.

Imaging studies were performed using a two-dimensional Doppler Echocardiography system (VividQ, GE Healthcare, UK) and a cardiac magnetic resonance 3-T scanner (Siemens Healthcare, Erlangen, Germany) at baseline and 4 months after implantation. Then, swine were euthanized by an overdose of IV pentobarbitone according to the surgical facility standard protocols. The grafted LPA was harvested and stored in PBS on ice until transported to the laboratory. Tissues were either snap frozen in OCT or fixed in 4% (w/v) PFA before OCT or paraffin inclusion and histology analysis.

Immunohistochemistry of vascular graft conduits
For a general overview of the grafted LPA structure, we performed H&E and elastin staining. Azan Mallory staining was used for the detection of fibrosis in the explants. The occurrence of microcalcifications was assessed using Von Kossa (Millipore, UK, cat n: 1.00362.0001). Endothelial cells in the intima and mural cells in the tunica media were recognized using antibodies reported in Table S2. Images were captured using a Zeiss Axio Observer.Z1 equipped with a Zen Blue software.

Statistical analyses
Average values are plotted with group size value shown in figure legends. Statistical significance for differences between experimental groups was determined using Student’s t-test when comparing two groups and ANOVA with post-hoc when comparing more than two groups. Values were expressed as means±standard error of the mean (SEM) or standard deviation (SD). Probability values (P) <0.05 were considered significant. Results from the in vivo feasibility study are reported in a descriptive format.
Table S1. Code of donor neonatal swine and analyses performed on corresponding cardiac samples and isolated cells.

| Swine code | Weight (g) | Experimental use |
|------------|------------|------------------|
| 240617A    | 0.9        | Immunohisto-cytochemistry, PCR, ELISA, Migration assay w/o anti-Tie2 |
| 080717A    | 0.08       | Immunohisto-cytochemistry, PCR, Matrigel-co, Migration assay w/o anti-Tie2 |
| 080717B    | 0.08       | Immunocytochemistry, FACS, PCR, Matrigel-co/CM, ELISA, Migration assay without anti Tie2, EdU assay |
| 060917A    | 0.09       | Immunocytochemistry, Growth curve- Viability-DT, FACS, Clonogenic assay, PCR, Matrigel-co, ELISA |
| 060917B    | 0.09       | Growth curve- Viability-DT, FACS, Matrigel-co/CM, ELISA, Migration assay without anti-Tie2, EdU assay |
| 060917C    | 0.09       | Immunocytochemistry, Growth curve -Viability-DT, Clonogenic assay |
| 140618A    | 0.2        | PCR, Matrigel-CM, Migration assay-anti-Tie2, EdU assay |
| 190618A    | 0.013      | Immunocytochemistry, Matrigel-CM, Migration assay-anti-Tie2, EdU assay |
| 240718A    | 0.01       | Immunocytochemistry |
### Table S2. Antibodies used in immunohistochemistry and immunocytochemistry studies.

| Marker | Technique | Permeabilization | Reactivity | Primary antibody source and dilution | Secondary antibody source |
|--------|-----------|------------------|------------|--------------------------------------|---------------------------|
| α-SMA  | ICC-IF, IHC-IF | Yes              | Human/Swine | Sigma, 1:400                           | Cy3-conjugated            |
| Calponin | ICC-IF, IHC-IF | Yes              | Human/swine | Abcam, 1:100                          | Invitrogen, A488 Goat α-Rabbit |
| CD31   | ICC-IF     | Yes              | Swine      | Abcam, 1:20                           | Invitrogen, A488 Goat α-Rabbit |
| CD31   | IHC-IF     | No               | Human      | R&D, 1:50                             | Invitrogen A647 highly adsorbed Goat α-mouse |
| CD34   | IHC-IF     | Yes              | Swine      | Abcam, 1:100                          | Invitrogen A488 Goat α-Rabbit |
| CD73   | ICC-IF     | Yes              | Swine      | R&D, 1:10                             | Invitrogen, APC donkey anti-sheep |
| CD146  | ICC-IF     | Yes              | Human/Swine | Abcam, 1:100                          | Invitrogen, A488 Goat α-Rabbit |
| GATA-4 | ICC-IF     | Yes              | Human      | Abcam, 1:100                          | Invitrogen, A488 Goat α-rabbit |
| NANOΓ  | ICC-IF     | Yes              | Human      | Abcam, 1:100                          | Invitrogen, A488 Goat α-mouse |
| NG2    | ICC-IF, IHC-IF | Yes            | Swine      | NovusBiological, 1:50                 | Invitrogen, A488 Goat α-Rabbit |
| OCT-4  | ICC-IF     | Yes              | Human/Swine | Abcam, 1:100                          | Invitrogen, A488 Goat α-Rabbit |
| PDGFRβ | ICC-IF     | Yes              | Swine      | GeneTex, 1:100                        | Invitrogen, A488 Goat α-Mouse |
| SMMHC11| ICC-IF, IHC-IF | Yes          | Human/swine | Abcam, 1:100                          | Invitrogen, A488 Goat α-Rabbit |
| Smoothelin | ICC-IF, IHC-IF | Yes        | Human/swine | Santa-Cruz, 1:100                     | Invitrogen, A488 Goat α-Mouse |
| SOX2   | ICC-IF     | Yes              | Human/Swine | Merck Millipore, 1:100               | Invitrogen, A488 Goat α-Rabbit |
| Transgelin | ICC-IF, IHC-IF | Yes         | Human      | Santa-Cruz, 1:50                      | Invitrogen, A488 Goat α-Mouse |
| VE-cadherin | ICC-IF   | Yes              | Human/Swine | Santa Cruz, 1:50                      | Invitrogen, A488 Goat α-Mouse |
| Vimentin | ICC-IF      | Yes              | Human      | Abcam, 1:400                          | Invitrogen, A488 Goat α-Rabbit |
Table S3. Antibodies used in flow cytometry studies.

| Marker   | Permeabilization | Reactivity | Primary antibody source dilution | Fluorophores                          |
|----------|------------------|------------|----------------------------------|---------------------------------------|
| CD31     | No               | Swine      | Serotec, 1:80                    | PE                                    |
| CD44     | No               | Swine      | eBioscience, 1:20                | APC                                   |
| CD45     | No               | Swine      | Serotec, 1:25                    | FITC                                  |
| CD73     | No               | Swine      | R&D, 1:10                        | Invitrogen, APC donkey anti-sheep     |
| CD90     | No               | Swine      | eBioscience, 1:20                | Pe-Cy7                                |
| CD105    | No               | Swine      | LifeSpan, 1:5                    | PE                                    |
| CD146    | No               | Swine      | Serotec, 1:60                    | FITC                                  |
| PDGFRβ   | No               | Human      | Biolegend, 1:25                  | PE                                    |
| Dye eFluor 780 | No |             | eBioscience, 1:1000              | APC-Cy7                               |
Table S4. TaqMan probes used in the molecular biology studies.

| Gene       | Species | Assay ID          |
|------------|---------|-------------------|
| ANG1       | Swine   | Ss03391075_m1     |
| ANG2       | Swine   | Ss03392362_m1     |
| PPIA (housekeeper) | Swine | Ss03394782_g1     |
| VEGF-A     | Swine   | Ss0339390_m1      |
Table S5. Analyses performed on sCP-engineered grafts.

| Swine code | Post-static                                                                 | Post-dynamic                                                                 | In vivo                      |
|------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------------------------|
| 240617A    | H&E, EVG, Collagen, Proliferation, Apoptosis, NG2 and VSMC markers          | H&E, EVG, Collagen, Proliferation, Apoptosis, NG2, VSMC markers, and Mechanical tests |                             |
| 080717A    | Collagen                                                                     |                                                                              |                             |
| 080717B    | Viability, H&E, EVG, Collagen, Proliferation, Apoptosis, NG2 and VSMC markers | Viability, H&E, EVG, Collagen, Proliferation, Apoptosis, NG2 and VSMC markers |                             |
| 060917A    | H&E, EVG, Collagen, Proliferation, Apoptosis, NG2 and VSMC markers          | H&E, EVG, Collagen, Proliferation, Apoptosis, NG2, VSMC markers, and Mechanical tests |                             |
| 060917B    | H&E, EVG, Collagen, Proliferation, Apoptosis, NG2 and VSMC markers          | H&E, EVG, Collagen, Proliferation, Apoptosis, NG2, VSMC markers, and Mechanical tests |                             |
| 191217A    | Viability                                                                    |                                                                              |                             |
| 140618A    | Viability, H&E, EVG, Collagen, Proliferation, Apoptosis, NG2 and VSMC markers | Viability                                                                    | Engraftment                 |
| 190618A    | Viability, H&E, EVG, Collagen, Proliferation, Apoptosis, NG2 and VSMC markers | Viability                                                                    | Engraftment                 |
| 240718A    | Viability, H&E, EVG, Collagen, Proliferation, Apoptosis, NG2 and VSMC markers | Viability                                                                    | Engraftment                 |
| 050918A    | H&E, EVG, Collagen, Proliferation, Apoptosis, NG2 and VSMC markers          |                                                                              | Engraftment                 |
| 050918B    | H&E, EVG, Collagen, Proliferation, Apoptosis, NG2 and VSMC markers          |                                                                              | Engraftment                 |
| 30.01.19A  | Viability                                                                    |                                                                              | Engraftment                 |
| 30.01.19 B | Viability                                                                    |                                                                              | Engraftment                 |
| Unseeded Graft | Viability, H&E, EVG, Collagen, Proliferation, Apoptosis, NG2 and VSMC markers | Viability, H&E, EVG, Collagen, Proliferation, Apoptosis, NG2, VSMC markers, and Mechanical tests | Engraftment                 |